From 1 November 2020, siponimod (Mayzent) will be available on the Pharmaceutical Benefits Scheme (PBS) for adults with secondary progressive multiple sclerosis (SPMS).1 Siponimod is the first approved and PBS-listed medicine for adults with SPMS in Australia.1

The Mayzent Experience Program will be closed for new patient enrolments on 31 October 2020. PBS scripts can be written from 1 November 2020 for eligible patients.

The MSGo Patient Support Program will remain active. The program has a dedicated nurse who will support healthcare professionals and patients when initiating treatment.  

Reference

  1. Department of Health, Pharmaceutical Benefits Scheme. Available at: www.pbs.gov.au

Case scenario

Melissa is a 28 year old usually fit and he

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.